The Wyss Institute at Harvard University announced today that Ropirio Therapeutics, Inc. (Ropirio) has secured a worldwide, exclusive license from Harvard’s Office of Technology Development (OTD) and Boston University (BU)’s Technology Development office for novel molecules that activate the lymphatic system – a first in the pharma industry.
CPHI Europe: Targeting supply chain bottlenecks key for cell and gene therapies – Pharmaceutical Technology
Image caption: Shutterstock/AuthenticVision Cell therapies stand at the frontier of medicine and hold the potential to potentially cure diseases, said Angela Vollstedt, global director of
October 11, 2024